Explore the words cloud of the GLUCOSTAT project. It provides you a very rough idea of what is the project "GLUCOSTAT" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||3˙571˙137 €|
|EC max contribution||2˙499˙796 € (70%)|
1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
|Duration (year-month-day)||from 2017-11-01 to 2020-08-31|
Take a look of project's partnership.
The GLUCOSTAT project will develop a first to the market, fully integrated, biotechnology device that will enable automatic control of blood glucose levels for patients in ICUs. This will improve the clinical outcomes for the patient as their blood glucose concentration will be maintained in the healthy normal concentration range (4-6 mM). Automatic blood glucose control will also decrease the workload on nurses as they no longer need to take frequent blood samples which will allow this valuable resource to be re-directed to more valuable roles within the intensive care wards. A move away from discrete sampling to an automatic control system that maintains low fluctuations will result in a cost reduction of €2,638 per intensive care unit (ICU) patient and hence be more resource and labour efficient. With an estimated 1.25 million sepsis/diabetes patients in the EU who will most benefit from continuous glucose monitoring (CGM), the total cost savings of implementing GLUCOSTAT will be in the order of €3.3 billion. The GLUCOSTAT project will optimise FLOW’s existing Diramo system and process used for its manufacture, and integrate the advanced control algorithm from Technical University of Denmark (DTU) to enable FLOW to apply for CE certification. The performance of the optimised CE marked device will then be evaluated by performing a clinical study where we will automatically control the blood glucose level of ICU patients to stay within the normal 4-6 mM range. This will demonstrate the automated blood glucose control system’s effectiveness in terms of delivering good accuracy, usability and robustness, which will enable FLOW to carry out post project commercialisation and market activities. Once the automatic control system has been launched, penetrated the market, and proved itself in patients with sepsis and diabetes, a market potential of €4.5 billion can be achieved for FLOW by implementing the device across all ICU patients in the EU and USA.
|Web page||Websites, patent fillings, videos etc.||2019-11-13 10:01:48|
|Press Release||Documents, reports||2019-11-13 10:01:48|
Take a look to the deliverables list in detail: detailed list of GLUCOSTAT deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOSTAT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLUCOSTAT" are provided by the European Opendata Portal: CORDIS opendata.